Covaxin

Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) fell 2% in Tuesday’s regular trading session after seeing strong gains on Monday. What Happened: Ocugen’s stock fell more than 2% to $9.15 in Tuesday’s trading on disappointing news related to Covaxin, the COVID-19...

Shares of Ocugen Inc. (NASDAQ: OCGN) surged almost 12.3% in Monday’s regular trading session and another 38.5% in the after-hours session in anticipation of a key event taking place Tuesday. What Happened: Ocugen's shares saw notable gains on Monday ahead of a key meeting on...

Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 18.5% in Tuesday’s regular trading session, extending gains to a second straight day. What Happened: Ocugen’s shares extended their rally on Tuesday after it was reported that an expert panel of India’s...

Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday’s regular trading session and also gained 11.4% in the after-hours session. What Happened: Ocugen’s shares rallied on Monday despite no company-specific news. The stock could have gained amid...

Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling submission of its regulatory application for its COVID-19 vaccine candidate Covaxin in Canada. Ocugen is co-developing...

Ocugen Inc (NASDAQ: OCGN) shares traded 74.1% higher at $9.14 at press time in the pre-market session on Monday. The surge comes as the biopharmaceutical company announced the sale of 3 million shares of its common stock in a registered direct offering to healthcare-focused institutional investors...

Ocugen Inc (NASDAQ: OCGN) shares were advancing sharply Tuesday on above-average volume. Ocugen, a gene therapy company, said it has executed a definitive agreement with India's Bharat Biotech to co-develop, supply and commercialize the latter's Covaxin in the U.S. Covaxin is an...